GoodRx is monitoring seven potential FDA drug approvals in 2025, including a possible expanded label for Ozempic. Here are this year's most anticipated approval decisions, according to a GoodRx ...

The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...

Patients with acute myocardial infarction are at a high risk of heart failure and death. Despite advances in care and reduction in the rate of recurrent myocardial infarctions, the risk for heart ...

In a disclaimer, GoodRx noted that the list was created by prioritizing "first-in-class medications and vaccines that are expected to have a significant impact on human health." "This was defined ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco. SANTA MONICA, Calif., January 10, 2025--GoodRx (Nasdaq: GDRX), the leading ...

As anyone who’s ever had a yeast infection can attest, they’re an experience that’s best avoided. Also known as vaginal candidiasis, an overgrowth of yeast is their most common cause ...

Empagliflozin (EMPA) inhibition on NHE activity was then assessed at pH of 7.0, 7.2 and 7.4. In addition, effects of 10 min PXIV treatment were also evaluated in H9c2 cells for EMPA and cariporide NHE ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...